Table 1 Is recurrence attack- or patient-dependent?
From: What can be learned from the history of recurrence in migraine? A comment
References | Methods | Result |
|---|---|---|
Rapoport et al. [22], Ferrari et al. [23], Scott et al. [24] | Administration of sumatriptan 100 mg or placebo as a second dose after 2–4 h for the prevention of recurrence | No effect of sumatriptan on the incidence of recurrence compared with placebo |
Visser et al. [26] | Analysis of 366 migraine patients | Recurrence more frequently with severe attacks and long duration of untreated attacks |
Visser et al. [1] | Pharmacokinetic and pharmacodynamic evaluation after subcutaneous sumatriptan in migraine patients outside attacks | No differences between patients with recurrence and non-recurrence patients |
Dodick et al. [27] | Multivariate logistic regression analysis identified predictors of headache recurrence in the eletriptan trial program | Predictors of recurrence were: >35Â years old, females, and severe attacks at baseline |
Tfelt-Hansen [32] | RCT of frovatriptan (t½ = 26 h) versus sumatriptan (t½ = 2 h) | Frovatriptan (25% recurrence) was not different from sumatriptan (31% recurrence)a |
Saxena and Tfelt-Hansen [16] | Comparative RCTs of a triptan versus ergot alkaloids | In five out of six RCTs significant less recurrence with ergot alkaloids than with a triptan |
Brandes et al. [25] | RCT of naproxen plus sumatriptan versus sumatriptan | More sustained pain-free (24%) after naproxen plus sumatriptan than after sumatriptan (15%) |